Epicardial Fat, Visceral Fat and Coronary Atherosclerosis

• Conditions: Epicardial Fat; Visceral Fat; Atherosclerosis
• Interventions: Other: patient with liver fat; Other: pts. with excess of visceral fat; Other: control

• Registration Number: NCT01344694
• Lead Sponsor: Ziv Hospital

Brief Summary

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear.

Detailed Description

Background: Visceral fat is increasingly associated with metabolic syndrome and with fatty liver, a condition carrying a high risk of cardiovascular disease. The independent role of epicardial fat deposition in cardiovascular risk remains unclear. Aim: Evaluate the link between epicardial fat, visceral fat, liver fat accumulation and cardiovascular diseases and carotis atherosclerosis in patients with the major cardiovascular risk factors and with or without metabolic syndrome.

Study Timeline

• Status Verified: 2011-04
• Study First Submitted: 2011-04-27
• Study First Submitted QC: 2011-04-28
• Study First Posted: 2011-04-29
• Last Update Submitted: 2011-05-13
• Last Update Posted: 2011-05-16
• Study Start: 2011-07
• Primary Completion: 2012-02
• Study Completion: 2012-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

• Patients referred to cardiac CT will be the source of recruitment.
• patients with excess of visceral fat,
• 30 patients with liver fat accumulation
• 30 sex-age-matched individual (controls) will be enrolled. All patients will undergo a complete family history, personal clinical history, physical examination and blood sampling for biochemical analysis.
• Informed consent will be obtained from each individual.

Exclusion Criteria

• subjects with severe morbid obesity (body mass index [BMI] > 40),
• recent history of acute illness,
• clinical history of ischemic heart disease and cerebrovascular disease,
• typical chest pain,
• previous coronary artery disease,
• conventional coronary angiography, percutaneous interventions, coronary by pass grafting, renal failure, cancer patients,
• subjects who take drugs that induces hepatic steatosis ( corticosteroids, estrogens, methotrexate, amiodarone and others)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patient with liver fat	patient with liver fat	30 patients with liver fat
excess of visceral fat	pts. with excess of visceral fat	50 pts. with excess of visceral fat
control	control	30 control subjects

Trial Locations

Locations (1)

Ziv MC; 🇮🇱 Safed, Israel